Q2 2024 INmune Bio Inc Earnings Call Transcript
Key Points
- INmune Bio Inc (INMB) has made steady progress in both its Alzheimer's and cancer programs, with promising interim data from the Phase 2 Alzheimer's trial.
- The company's Alzheimer's drug, XPro, is showing potential in improving synaptic function, which is crucial for cognitive health.
- INKmune, the company's cancer treatment, has demonstrated the ability to create cancer-killing memory-like NK cells, showing promise for treating solid tumors.
- The company successfully raised approximately $14.5 million in gross proceeds from equity offerings, strengthening its financial position.
- INmune Bio Inc (INMB) joined the Russell 3000 Index, which is expected to increase its visibility within the investment community.
- Enrollment for the Phase 2 Alzheimer's trial has taken longer than expected due to stringent patient selection criteria.
- The company's net loss increased to approximately $9.7 million for the quarter ended June 30, 2024, compared to $6.5 million for the same period in 2023.
- Research and development expenses rose significantly, totaling $7.1 million for the quarter, up from $4.1 million in the previous year.
- There is uncertainty regarding the EU's stance on anti-amyloid drugs, which could impact the Alzheimer's treatment landscape.
- The company faces challenges in manufacturing and scaling up its INKmune product, although steps are being taken to address these issues.
Greetings, and welcome to the INmune Bio second quarter 2024 earnings call. (Operator Instructions) As a reminder, this conference is being recorded. A transcript will follow within 24 hours of this conference call.
At this time it's my pleasure to introduce Mr. David Moss, CFO of INmune Bio. David?
Thank you, operator, and good afternoon, everyone. We thank you for joining us for the call for INmune Bio's second quarter 2024 financial results. With me on the call today are Dr. RJ Tesi, CEO and Co-Founder of INmune Bio; and Dr. Mark Lowdell, Chief Scientific Officer and Co-Founder of INmune Bio, who will provide an update on INKmune, our memory like natural killer cell oncology platform. Also on the call is Dr. CJ Barnum, Head of Neuroscience, who will provide some details on our ongoing Phase 2 Alzheimer's study.
Before we begin, I remind everyone that except for statements of historical facts, the statements made by management and responses to questions on this conference call are forward
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
